Contribute Try STAT+ Today

Yet another country has begun battling with Vertex Pharmaceuticals (VRTX) over its cystic fibrosis medicines. In a new report, an independent Canadian advisory group has rejected the use of the Orkambi treatment over questions about both its cost and clinical effectiveness.

In reaching its conclusion, the Canadian Agency for Drugs and Technologies in Health cited uncertainty over clinical trials measuring the extent to which the drug improved patient health; a lack of studies gauging the effect Orkambi has on a need for lung transplants or survival; and no statistically significant improvements in health-related quality of life based on patient questionnaires, among other things.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.